Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

Table 2 Surgical outcomes

	PET-CMR, n = 22	Non-PET-CMR, n = 36	P value
Esophagectomy procedures
Subtotal	20	32	0.31
Cervical	1	0
Pharyngeal laryngeal	1	4
LN dissection
Cervical	1	2	0.89
2 fields	5	10
3 fields	16	24
Harvested LN1	72 ± 7	73 ± 5	0.91
Blood loss in mL1	559 ± 219	836 ± 540	0.026
OP time in min1	527 ± 105	580 ± 121	0.092
Curability
R0	22	29	0.027
R1	0	7
Intraoperative complication
Bronchus injury	1	1	0.72
Postoperative complication
All	14	22	0.85
Anastomotic leakage2	1	1	0.72
Anastomotic stenosis2	2	3	0.92
Recurrent nerve palsy2	7	12	0.91
Respiratory2	3	8	0.42
Others2	2	3	0.92
Surgical mortality	0	0	-

¹mean ± SD.

²Clavien-Dindo Classification ≥ 3.

LN: Lymph node; OP: Operation; PET-CMR: Positron emission tomography-complete metabolic response.